Gerontology, Palliative Care & Prevention · Topic 7 of 13

Palliative Symptom Management

Palliative care · symptoms near death

Palliative Symptom Management

Comfort first: low-dose opioids for dyspnea, anticholinergics for secretions, haloperidol for agitated terminal delirium, and scheduled opioids with breakthrough doses for pain.

Key numbers

Opioids are first-line for terminal dyspneamorphine ≤ 2 mg IV

Glycopyrrolate 0.2–0.4 mg for terminal secretions0.2–0.4 mg IV/SC q4h

Haloperidol first for agitated terminal delirium< 8 mg/day scheduled

Inadequate opioid dose: increase 1.5–2 times× 1.5–2 daily dose

01 · GiveOpioids are first-line for terminal dyspnea

Opioids are the drugs of choice for dyspnea near death: in an opioid-naive patient, morphine ≤ 2 mg parenteral or ≤ 5 mg oral; for acute severe dyspnea, 1–3 mg IV every 30–60 minutes as needed.

02 · GiveGlycopyrrolate 0.2–0.4 mg for terminal secretions

For terminal secretions, give an anticholinergic: glycopyrrolate 0.2–0.4 mg IV or subcut every 4 hours as needed does not cross the blood–brain barrier, so it causes less sedation and delirium.

03 · GiveHaloperidol first for agitated terminal delirium

For agitated end-of-life delirium, schedule low-dose parenteral haloperidol (under 8 mg/day) with rescue doses up to hourly; terminal delirium is usually irreversible, so do not chase causes in a clearly dying patient.

The rules

Know these

Dying on comfort care: stop oximetry, ABGs, imagingWhen death is expected and the goal is comfort, pulse oximetry, arterial blood gases, ECGs and imaging are not indicated — treat the reported symptom.

Artificial nutrition does not prolong dyingIV fluids and artificial nutrition do not prolong life in the dying and can cause edema, pulmonary congestion and secretions; relieve dry mouth with oral care and ice chips.

Management

Orders

Schedule opioids, plus short-acting breakthrough doses must knowTreat persistent pain with opioids on a continuous schedule (long-acting once stable) plus short-acting doses for breakthrough and anticipated painful care; a history of substance use does not justify withholding them.

Already on opioids: raise the dose for dyspneaA patient already taking opioids needs more for new dyspnea — raise the baseline opioid dose by 25–50%; dyspnea doses may need to be up to double the usual dose.

Fan, upright position; oxygen only if it helpsSit the patient up and move air with a fan or open window; judge oxygen by relief, not oximetry — it adds nothing over room air when normoxic — and prefer nasal cannula to a mask.

Benzodiazepines for the anxiety of dyspneaAdd a benzodiazepine (e.g., lorazepam) for the anxiety that accompanies dyspnea and the fear of its return — an adjunct to the opioid, not a replacement.

Death rattle: reposition, limit fluids, skip deep suctionFor the death rattle, turn the patient to the side or semiprone, limit IV and enteral fluids and avoid deep suctioning; explain to the family that the sound is not usually distressing to the patient.

Scopolamine patch 1.5 mg every 72 hoursTransdermal scopolamine 1.5 mg every 72 hours behind the ear is an alternative for secretions; it takes about 12 hours to work, crosses into the brain and is sedating, so it suits a short prognosis.

Refractory agitation: escalate, then palliative sedationIf agitation persists, increase haloperidol, switch to chlorpromazine or add lorazepam; for refractory agitation, continuous palliative sedation (e.g., midazolam infusion, or a barbiturate) after discussion with the family.

Calm, comfortable confusion may need no drugReorientation, a calm familiar presence and fewer psychoactive drugs prevent and soften delirium; a dying patient who is confused or calmly hallucinating but comfortable may do better with no medication.

Inadequate opioid dose: increase 1.5–2 timesWhen a stable opioid dose stops working, increase the daily dose 1.5- to 2-fold; serious respiratory depression usually occurs only when the increase is much more than double the tolerated dose.

Start a bowel regimen with every opioidTreat opioid-induced constipation prophylactically — a stimulant laxative such as senna twice daily, or an osmotic laxative (lactulose) if cramping; little tolerance develops to opioid constipation.

Match the antiemetic to the nausea causeTreat nausea by cause: metoclopramide for gastric stasis, dexamethasone for brain metastases, ondansetron or prochlorperazine for nonspecific nausea, and haloperidol for intractable nausea.

Malignant bowel obstruction: octreotide plus dexamethasoneIn malignant bowel obstruction, octreotide cuts secretions and distention and, with antiemetics, usually avoids nasogastric suction; dexamethasone may shrink obstructing edema.

Red flags & don'ts

Avoid harm

Opioid neurotoxicity: rotate to another opioid complicationMyoclonus, hyperalgesia, hyperactive delirium or seizures on opioids suggest toxic metabolite accumulation — rotate to a different opioid using morphine equivalents.

Glycopyrrolate or scopolamine for secretions?

Commonly confused

Dose	0.2–0.4 mg IV or subcut every 4 h as needed
Onset	About 1 minute
Crosses blood–brain barrier	No (quaternary amine)
CNS effects	Fewer — less sedation and delirium

More detail

Reference

Show 6 reference facts

Nebulized morphine has not outperformed subcutaneous morphine for dyspnea in a controlled trial; use systemic opioids.

Scopolamine, atropine and hyoscyamine are tertiary amines that cross the blood–brain barrier (more sedation, delirium and heart-rate effects); glycopyrrolate is a quaternary amine that does not.

In a placebo-controlled trial of mild-to-moderate delirium in palliative care, oral risperidone or haloperidol worsened delirium symptoms and extrapyramidal effects — reserve antipsychotics for distressing agitation.

Properly titrated opioids for terminal dyspnea have not been shown to hasten death; relieving symptoms is ethical even if death is foreseen but not intended (double effect).

For depression with a prognosis longer than the 2–4 weeks antidepressants need, try an antidepressant; methylphenidate gives rapid energy for fatigue or somnolence in the last weeks.

Opioid risk-mitigation tools such as prescription monitoring checks and naloxone co-prescribing are usually not necessary for dying patients.

Pearl

Treat the symptom, not the number: when death is near and the goal is comfort, put away the oximeter and reach for the morphine and the fan.

Sources · Merck Manual Professional — Symptom Relief for the Dying Patient (May 2026) · Palliative Care Network of Wisconsin Fast Fact #27 — Dyspnea at End-of-Life (2024) · Palliative Care Network of Wisconsin Fast Fact — Death Rattle and Oral Secretions · Hui D et al. Pharmacologic Management of End-of-Life Delirium: Translating Evidence into Practice. Cancers 2024;16:2045 · Agar MR et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium in palliative care: RCT. JAMA Intern Med 2017;177:34–42 (Europe PMC abstract) · Merck Manual Professional — The Dying Patient (May 2026) · Starter sheet built from the verified AGACNP fact map (facts reviewed 2026-10-15).